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Recent evidence suggests that most malignancies are driven by ‘‘cancer stem cells’’ sharing
the signature characteristics of adult stem cells: the ability to self renew and to differentiate.
Furthermore these cells are thought to be quiescent, infrequently dividing cells with a natural
resistance to chemotherapeutic agents. These studies theorize that therapies, which effectively
treat the majority of tumor cells but ‘miss’ the stem cell population, will fail, while therapies
directed at stern cells can potentially eradicate tumors. In breast cancer, researchers have iso-
lated ‘breast cancer stem cells’ capable of recreating the tumor in vivo and in vitro. Gener-
ated new tumors contained both additional numbers of cancer stem cells and diverse mixed
populations of cells present in the initial tumor, supporting the intriguing self-renewal and dif-
ferentiation characteristics. In the present study, an antibody phage library has been used to
search for phage displayed-single chain antibodies (scFv) with selective affinity to specific tar-
gets on breast cancer stem cells. We demonstrate evidence of two clones binding specifically
to a cancer stem cell population isolated from the SUMl59 breast cancer cell line. These
clones had selective affinity for cancer stem cells and they were able to select cancer stem
cells among a large population of non-stem cancer cells in paraffin-embedded sections. The
applicability of these clones to paraffin sections and frozen tissue specimens made them good
candidates to be used as diagnostic and prognostic markers in breast cancer patient samples
taking into consideration the cancer stern cell concept in tumor biology. VC 2009 American
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Introduction
Recently, there is accumulating evidence supporting the
‘‘cancer stem cell hypothesis’’ stating that a tumor is hier-
archically organized with its own stem cell compartment
called ‘‘cancer stem cells.’’ These cancer stem cells drive tu-
morigenesis and give rise to a large population of differenti-
ated progeny that makes up the bulk of the tumor. This
model, first developed in human myeloid leukemia, is now
extended to solid tumors including breast, brain, prostate,
gastrointestinal cancers, head and neck tumors, and mela-
noma.1,2 In addition, it has been reported that established
cancer cell lines also retain a small population of cells mim-
icking cancer stem cell behavior.3,4
Cancer stem cells with their self renewal and differentia-
tion capacity and their relative resistance to chemo and
radiotherapy may be the only cells in a malignancy with the
ability to promote tumor growth, distant organ metastasis,
and multidrug resistance, leading to failure of treatment and
ultimately returning of the disease. Therefore, to achieve
better antineoplastic therapies with decreased morbidity and
mortality, we need novel therapeutic regimens targeting
cancer stem cells.
Additional Supporting Information may be found in the online ver-
sion of this article.
Correspondence concerning this article should be addressed to
D. Krag at david.krag@uvm.edu.
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Our goal is to use bacteriphage display technology to
develop a set of ligands binding specifically to cancer stem
cells. We believe that identification of clinically relevant
ligands with selective affinity to specific targets on breast
cancer stem cells may be used as novel diagnostic and thera-
peutic tools in breast cancer management.
In this study, we demonstrate evidence of two unique
clones binding specifically to ‘‘cancer stem cells.’’ These
clones have been isolated from a scFv phage library after a
series of panning on ‘‘cancer stem cells.’’ Cancer stem cell
population has been sorted from SUM159 breast cancer cell
line by utilizing Aldefluor assay, which detects cells express-
ing stem cell marker aldehyde dehydrogenase. It has been
shown by Wicha and coworkers5 that Aldefluor positive cells
isolated from human breast tumors contain cancer stem cell
population able to self renew and recapitulate the heteroge-
neity of the parental tumor. In addition, aldehyde dehydro-
genase 1 (ALDH1) expression is found to be a predictor of
poor clinical outcome for breast cancer patients.5 Our two
clones showed specific binding to Aldefluor positive cancer
stem cell population and they were able to select ALDH1
positive cells among a large population of ALDH1 negative
cells in paraffin-embedded tissue sections.
Material and Methods
Cell line and tissue culture
SUM159 breast cancer cell line developed from a primary
anaplastic breast carcinoma was obtained from Dr. Stephen
Ethier (Kramanos Institute, MI). The cells were cultured in
Ham’s F12 media containing glutamine with 5% fetal bovine
serum, insulin (5 lg/mL), and hydrocortisone (2 lg/mL). It
was grown at 37C and 5% CO2.
Xenotransplantation and harvesting of tumor from
NOD/SCID mice
Five female NOD/SCID mice at 7–9 weeks of age were
purchased from Charles River Laboratories (Wilmington,
MA) and maintained under specific pathogen free conditions
at the University of Vermont. Animals were used in accord-
ance with the Institutional Animal Care and Use Committee
(IACUC) at the University of Vermont. The mammary fat
pads of mice were cleared as described previously.5 On the
day of transplantation, SUM159 cells were trypsinized,
washed, and cells were resuspended in matrigel (BD Bio-
sciences). A total of 4  106 cells in 40 lL matrigel were
subcutaneously transplanted in the cleared mammary fat
pads of mice. The mice were monitored every week and
when the tumor size reached 1 cm in diameter, animals were
euthanized in CO2 chamber and tumor tissue was harvested.
Aldefluor assay and separation of ALDH positive
cells by FACS
The ALDEFLUOR kit (StemCell Technologies, Durham,
NC) was used to isolate the population with a high ALDH
enzymatic activity. Cells were trypsinized when they were
80% confluent and were suspended in ALDEFLUOR assay
buffer containing ALDH substrate (BAAA, 1 mmol/L per
1  106 cells) and incubated for 40 min at 37C. As nega-
tive control, for each sample of cells, an aliquot was treated
with 50 mmol/L diethylaminobenzaldehyde (DEAB), a spe-
cific ALDH inhibitor. These cells were used as negative con-
trols to establish the sorting gates. Propium iodide (PI)
(1 lg/mL) (Sigma Aldrich) was used to assess cell viability.
Phage library
A single-chain antibody (scFv, Tomlinson I) library was
used for panning on Aldefluor positive cancer stem cells.
scFv sequences in these libraries were expressed as NH2
terminus fusion to minor coat pIII protein of filamentous
bacteriophage. The trypsin cleavable human single-fold scFv
Tomlinson I library, cloned in ampicillin-resistant phagemid
vector pIT2 and transformed into TG1 E. coli cells, was
obtained from MRC, HGMP Resource Centre (Hinxton,
Cambridge, United Kingdom). The scFv fragments compose
a single polypeptide with the VH and VL domains attached
to each other by flexible glycine–serine linker. scFv library
has diversity of 1.47  108. The scFv library amplification,
titration, elution of cell-bound phage, and their plating were
done as previously described using KM13 helper phage.6–8
Biopanning on Aldefluor positive cancer stem cells
We conducted biopanning on FACS sorted Aldefluor posi-
tive cancer stem cells in a 0.5 mL centrifugal filter cup with
0.65 lm low binding Durapore PVDF membrane (Millipore,
Bedford, MA). FACS sorted Aldefluor positive and negative
SUM159 cells were washed and fixed in 4% paraformalde-
hyde made in PBS. After washing paraformaldehyde away
with PBS, 50,000 Aldefluor negative and 20,000 Aldefluor
positive cells suspended in 1% casein blocker (Pierce, Rock-
ford, IL) transferred into two separate filter cups. Both filter
cups were incubated overnight at 4C to block cells. The
cup containing Aldefluor negative breast cancer cells was
centrifuged and an aliquot (1  1012 TU) of Tomlinson I
scFv library in biopanning buffer (0.2% casein, 0.05%
Tween-20, and 10% goat serum in TBS) was added. The
cells were incubated for 2 h with slow shaking at RT. This
negative subtraction step depletes scFv-phages that bind to
Aldefluor negative cell population, filter plastic, and mem-
brane. The filter cups with their collecting tubes were centri-
fuged and subtracted scFv library was transferred to the
other casein-blocked filter cup containing 20,000 Aldefluor
positive cancer stem cells. Cancer stem cells were incubated
for 2 h with slow shaking at RT. The tumor cells were
washed 10 times with 0.6 mL TBST (TBS 25 mm Tris-HCl,
150 mm NaCl, pH 7.4; with 0.05%Tween-20) and once with
TBS. The trypsin elution, plating, and amplification of
phages were done as described earlier.6–8 The amplified,
eluted, phage pool was used as input for the next round of
panning. Panning was repeated five rounds. The eluted
phages from fifth round of selection were plated on ampicil-
lin plates for isolation and identification of individual clone
binders.
Binding assessment of phage monoclones to Aldefluor
positive cells
Binding assessment of individual clones isolated from fifth
round of panning was done in a 96-well plate with a 5.0 lm
pore size polycarbonate membrane support. (Corning, NY).
One thousand Aldefluor positive and negative cells were
fixed with 4% paraformaldehyde made in PBS, washed, and
put into each filtered well. Before incubation with cells,
phage supernatants from individual clones were normalized
by chemiluminescence ELISA method developed in our
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laboratory.9 Normalized phage supernatant (50 lL) were
mixed with 50 lL of binding buffer (2 TBS, 0.1%Tween-
20, 20% goat serum, and 0.4% casein blocker) and incubated
with cells overnight at 4C, on a slow rotator. Unselected
scFv library was used as a negative control. The next day
cells were washed four times with TBS containing 0.05%
Igepal (TBS-Igepal) and incubated with polyclonal rabbit
anti M13 antibody (Sigma-Aldrich; 1:100 dilutions) in TBS-
Igepal for 1 h at room temperature. After washing, the cells
were incubated with chicken anti-rabbit/Alexa Fluor 488
conjugate (Molecular Probes, Carlsbad, CA) in TBS-Igepal
(1:400). Cells were washed six times with TBS-Igepal before
immunofluorescence or confocal microscopy.
For ALDH1 immunostaining, ALDH1 antibody (BD bio-
sciences) used at 1:25 dilution and goat antimouse/Alexa-
fluor 568 conjugate was used as the secondary antibody
(1:400).
Binding assessment of individual clones to cancer
stem cells
Either trypsinized, unsorted-SUM159 cells or paraffin-
embedded sections of SUM159 cells or frozen xenograft
tumors from mice were used. Trypsinized cells were fixed
with 100% ice cold methanol. Frozen tissue sections of xen-
ograft tumors were mildly fixed with 2% paraformaldehyde.
Paraffin sections were deparaffinized in xylene and rehy-
drated in graded alcohol and followed by antigen retrieval
by microwaving (Sharp Carousel) sections in citrate buffer
(pH 6) at low power for 5 min. Both cells and tissue sections
Figure 1. Representative FACS analysis of SUM159 cells using Aldefluor assay.
Cells incubated with Aldefluor substrate (BAAA) and the specific inhibitor of ALDH, DEAB. Cells incubated with DEAB were used to establish the
baseline fluorescence and to define aldeflour positive region. Incubation of cells with Aldefluor substrate in the absence of DEAB induces a shift in
defining the Aldefluor positive population (5.96%).
Figure 2. Immunofluorescence staining or clone 207 and clone 208 on Aldefluor positive and negative cell populations.
Unselected scFv library was used as a negative control. Both clones had higher binding to Aldefluor positive cells compared with aldefluor negative
population.
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were incubated with selected phage clones as described pre-
viously and immunostaining was done with antibody cock-
tails of ALDH1 and anti-M13 and appropriate secondary
antibodies as stated previously. Tissue sections of tumors
harvested from mice were stained with anti-M13 after phage
incubation.
Results
Isolation of Aldefluor positive cell population from
SUM159 cancer cell line
SUM159 cells were removed from tissue culture plates by
trypsinization when they became 80% confluent and ALDE-
FLUOR assay was utilized to detect and sort out the cancer
cells with high-ALDH enzymatic activity. The average per-
centage of Aldefluor positive cells in the unsorted population
was 5.6% (5.6  1.8) and these Aldefluor positive cells were
used both in panning and screening experiments (Figure 1).
Isolation of scFv expressing phage clones binding to
Aldefluor positive cancer cells
The Tomlinson I scFv phage library was used to select
cancer stem cell binding phages. For each round of selection,
the scFv library was first preabsorbed with Aldefluor nega-
tive cells. 1  1012 TU of scFv phage was incubated with
Figure 3. Immunostaining of FACS sorted cells with ALDH1 and candidate clones.
All the aldefluor positive cells were expressing higher levels of ALDH1 compared with aldefluor negative cell population. Both clone 207 and 208
had higher binding to ALDH1 positive cells compared with ALDH1 negative cells. Unselected scFV library was used as a negative control.
It showed much lesser binding on ALDH1 positive cell population compared with both clone 207 and 208.
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5  104 Aldefluor negative cells for 2 h. This subtraction
step removed not only the binders of Aldefluor negative cell
population but also the phage clones binding to the filter
cup. Subsequently, the depleted library was panned with 2 
104 Aldefluor positive cells and phage eluted from each step
were amplified and used as the input of the next round of
panning. After five rounds of subtractive selection, isolated
clones from fifth panning output were further analyzed for
their specific binding ability to Aldefluor positive cells.
Binding assessment of scFv expressing phage monoclones
to Aldefluor positive cell population
Clones randomly isolated from the last round of biopan-
ning were amplified and after normalization of their concen-
tration, they were assessed for their binding to Aldefluor
positive cells by immunofluorescence imaging in 96-well
plates with a permeable polycarbonate membrane. The use of
96-well filter plates miniaturized the binding assay, so that as
few as, 1,000 Aldefluor positive cells/well were enough to
analyze the individual clones. Individual clones (171) were
analyzed and two of them, clone 207 and clone 208, clearly
showed higher binding to Aldefluor positive cell population,
compared with Aldefluor negative cells (Figure 2).
Next, we investigated whether ALDH1 could be used as a
marker for detecting cancer stem cells. All the Aldefluor
sorted cells were fixed and stained with an ALDH1 mono-
clonal antibody. Only the Aldefluor positive cells expressed
ALDH1, whereas Aldefluor negative population contained no
ALDH1 positive cells. Double staining with ALDH1 and a
polyclonal antibody against the M13 filamentous phage
showed that clone 207 and 208 were specifically binding to
ALDH1 positive cells (Figure 3, Suppl Figure 1).
Selective binding of clone 207 and 208 to ALDH1
positive cells
To further investigate the selective binding of clone 207
and 208 to ALDH1 positive cancer stem cells, we performed
double staining with ALDH1 and anti-M13 phage anti-
body on unsorted SUM159 cell line. Cells trypsinized from
Figure 4. Immunostaining on unsorted SUM159 cell line showing the selective binding of clone 207 and clone 208 to ALDH1 positive
cells.
(a–d) Cells treated with page clone 207 with the following staining: (a) dapi staining of nuclei, (b) Anti-M13, (c) Anti-ALDH1, (d) Merged image
of a–c. (e–h) Cells treated with clone 208 with the following staining: (e) Dapi staining of nuclei, (f) Anti-M13, (g) Anti-ALDH1, (h) Merged image
of e–g.
Figure 5. Immunostaining on paraffin embedded tissue sections of SUM159 cell line showing the selective binding of clone 207 and
208 to ALDH1 positive cells.
(a–d) Cells treated with phage clone 207 with the following staining: (a) Phase contrast, (b) Anti-ALDH1, (c) Anti-M13, (d) Merged image of b–c.
(e–h) Cells treated with clone 208 with the following staining: (e) Phase contrast, (f) Anti-ALDH1, (g) Anti-M13, (h) Merged image of f–g.
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tissue culture plates were fixed, incubated with clone 207
and 208, and then stained for detection of cancer stem cells
and binding of phage monoclones. Among the unsorted
SUM159 cells, both clones showed significantly higher bind-
ing to the ALDH1 positive cells when compared with the
unselected library clones. More importantly, both clones
could select and bind to ALDH1 positive cells with higher
intensity than the ALDH1 negative population (Figure 4).
Figure 6. SUM159 tumor xenografts in NOD/SCID mice.
(a) Tumor injection site and successful tumorigenesis. (b) Tumor growth on the injected site and no tumor growth on the opposite mammary gland
fat pad. (c) Well demarcated, multilobulated tumor nodule. (d) Excised tumor nodule, 1 cm in diameter.
Figure 7. Paraffin-embedded tissue sections from SUM159 tumor xenografts grown in NOD/SClD mice.
(a) Tissue incubated with clone 207 and stained with anti M13. (b) Tissue incubated with clone 208 and stained with anti M13. (c) Tissue incubated
with unselected scFV library and stained with anti M13. (d–f) Merged images of tissues stained with anti M13 and dapi. (g–h) Phase contast. (i)
Negative control.
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Similar immunostaining pattern was also observed when par-
affin-embedded tissue sections of unsorted SUM159 cells
were used (Figure 5).
Xenograft tumor growth in NOD/SCID mice and binding
of clone 207 and 208 to tumor tissue
NOD/SCID mice were injected with 4  106 SUM159
cells subcutaneously into the mammary gland fat pads. Pal-
pable tumor nodules first appeared 3 weeks after tumor
injection and they rapidly grew and reached 1 cm in diame-
ter in 2 weeks (Figure 6). Frozen tissue section prepared
from xenograft tumors were mildly fixed, incubated with
clone 207 and 208, and then stained for detection of cancer
stem cells and binding of phage monoclones. Both clones
showed positive binding to tumor cells, whereas no positive
fluorescence signal was detected on tissue sections incubated
with unselected scFv library (Figure 7).
Discussion
The ‘‘Cancer stem cell hypothesis’’ stemmed from the idea
that tumors are composed of functionally heterogeneous pop-
ulation of cells and among them only a minority of tumor
cells is able to regenerate the tumor and sustain its growth.
These cancer stem cells have the ability to self renew and
give rise to differentiated progeny. There is growing evidence
supporting that cancer stem cells are the cells responsible for
tumor chemoresistance and recurrence by virtue of their slow
cell cycle kinetics, transporter proteins, and antiapoptotic
mechanisms.10 Like many other investigators, these features
directed our efforts toward development of novel therapeutic
and diagnostic strategies targeting cancer stem cells.
Our goal is to provide a set of breast cancer stem cell
specific ligands which will accelerate understanding the
molecular biology of cancer stem cells, as well as lead to
generation of reagents useful for diagnosis and therapy. We
have chosen phage display technology to identify ‘‘cancer
stem cell’’ specific ligands because it is a relatively rapid
and high throughput process. Modifications previously devel-
oped in our laboratory11 to miniaturize the biopanning and
binding assays enabled us to do experiments with very lim-
ited number of cells which is one of the main obstacles of
working with cancer stem cells.
Recently, in addition to the presence of cancer stem cells
in solid human tumors, it has been shown that established
cancer cell lines also retain the cellular hierarchy characteris-
tic of primary breast tumors and contain a small population
of cells mimicking cancer stem cell behavior.3,4 Therefore,
we worked with SUM159 breast cancer cell line to isolate
cancer stem cells. This approach overcame the problems of
not only procuring and using primary human tissues but also
the difficulty of control because of the heterogeneity of their
cellular, genetic, and epigenetic composition.
Aldehyde dehydrogenase 1 (ALDH1), which is a detoxify-
ing enzyme responsible for the oxidation of intracellular
aldehydes has a role in early differentiation of stem cells. It
has been shown to be one of the markers used to isolate can-
cer stem cells from both primary human breast tumors and
breast cancer cell lines.5,12
We used the Aldefluor kit from Stem Cell Technologies
(Durham, NC) which isolates cancer stem cells based on
their high-aldehyde dehydrogenase activity. Aldefluor posi-
tive and negative cell populations sorted by FACS were used
in panning and clone analysis. After five rounds of panning
and screening on cancer stem cells, we were able to identify
two unique clones—clone 207 and 208—binding specifically
to Aldefluor positive cells. Both clones had higher binding
compared with unselected library clones and they also had
significantly higher signal on Aldefluor positive cells than on
Aldefluor negative population. More importantly, both clones
were able to select and bind to ALDH1 positive cancer stem
cells from unsorted SUM159 cell line 90% of which is
composed of ALDH1 negative non-stem cancer cells. When
the clones were incubated with unsorted SUM159 cell line,
they also showed some degree of immunostaining with the
ALDH1 negative cells. Although the binding was higher
than the unselected library clones, it was much lower than
the real positive signal detected on ALDH1 positive cancer
stem cells. Similar binding features were observed both with
the paraffin-embedded sections of SUM159 cell line and
tumor sections of xenografts grown in NOD/SCID mice
which made these clones good candidates for analysis of
archived breast cancer patient specimens. This is important
because it should allow definition of the relationship of
breast cancer stem cells to vascular and stromal elements.
This will also be an important tool to guide laser capture of
cancer stem cell in clinical specimens for genomic and
proteomic analysis which will help in understanding the
molecular biology behind cancer stem cells.
The applicability of clone 207 and 208 to paraffin-embed-
ded and frozen-tissue specimens may enable us to use them
as prognostic markers. Recent evidence demonstrates that
the percentage of cancer stem cells may dictate the aggres-
siveness and relapse potential of the tumor.5,12–14 In addition,
these ligands may be used as treatment follow-up markers in
select clinical situations. Most of the chemotherapeutic
agents used today for cancer treatment preferentially kill the
non-stem cancer cells that make up the bulk of the tumor.
Unfortunately, these treatments are sparing the cancer stem
cell population which is thought to be responsible for drug
resistance, failure of treatment, and recurrence of disease. As
a consequence of this type of therapeutic regimen, the tradi-
tional response criteria are the measurement of shrinkage in
tumor bulk. This approach may not reflect the changes in
smaller cancer stem cell population. Therefore, a dramatic
response may overestimate the effect of therapy. Clone 207
and 208 can select for the cancer stem cells and reflect the
effect of therapy on stem cell population. This may help the
development of new clinical approaches taking into account
the fate of cancer stem cells and help to modify the tradi-
tional measures of clinical response.
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